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When clopidogrel was first clinically used, the relation
between the pharmacodynamic effect and thrombotic event
occurrence was unknown. Moreover, when the new P2Y12
inhibitors were developed, the desired level of on-treatment
platelet reactivity to adenosine diphosphate to avoid isch-
emic event occurrence was highly debated and some recom-
mended that near-100% inhibition should be the target.
Concern surrounding the clinical implications of aggregometry-
defined poor platelet inhibition in clopidogrel-treated elec-
tive percutaneous coronary intervention (PCI) patients arose
over 1 decade ago (1). In that study, approximately 30% had
a10% decrease in aggregation at 24 h after a 300-mg load;
these patients were defined as resistant. It was suggested
that, “further study is necessary to investigate the mecha-
nisms of these findings and how they correlate with the
occurrence of ischemic events” (1).
See page 281
Aggregometry-defined clopidogrel nonresponsiveness
was first studied in relation to post-PCI ischemic event
occurrence in ST-segment elevation myocardial infarction
*Editorials published in JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-
ions or the American College of Cardiology.
From the †Sinai Center for Thrombosis Research, Sinai Hospital of Baltimore,
altimore, Maryland; and the ‡Interventional Cardio-Angiology Unit, GVM Care
nd Research, Cotignola, Ravenna, Italy. Dr. Tantry has received honoraria from
ayer and Accumetrics. Dr. Jeong has received honoraria for lectures from Sanofi-
ventis, Daiichi Sankyo, Inc., and Otsuka. Dr. Navarese has reported that he has no
elationships relevant to the contents of this paper to disclose. Dr. Gurbel has received
esearch grants, honoraria, and consultant fees from AstraZeneca, Merck, Medtronic,
li Lilly/Daiichi Sankyo, Inc., Sanofi-Aventis/Bristol-Myers Squibb, Portola/
ovartis, Boston Scientific, Bayer, Accumetrics, Boehringer Ingelheim, and Johnson
Johnson.patients (2). On-treatment reactivity was subsequently sug-
gested as a better ischemic risk predictor than nonrespon-
siveness, because risk was potentially overestimated in pa-
tients with low pre-treatment platelet reactivity and
underestimated in patients with high pre-treatment platelet
reactivity (3).
How far have we come since 2004? Numerous studies
conducted globally in thousands of patients have measured
the intensity of the platelet response to adenosine diphos-
phate, reaching the identical conclusion: patients with high
on-treatment platelet reactivity (HPR), determined either
immediately before PCI or at the time of hospital discharge,
are at increased risk for short- and long-term ischemic event
occurrence (4). Platelet reactivity cutoff values have been
reported in a white paper for consideration in future
personalized antiplatelet therapy studies (4). Platelet func-
tion testing in PCI patients is now addressed in American
and European treatment guidelines (5,6). Early small tur-
bidimetric aggregometry-based studies demonstrated that
short- and long-term ischemic event occurrences, including
periprocedural myocardial infarction (MI) and stent throm-
bosis (ST), were not linearly related to on-treatment platelet
reactivity but instead occurred above a moderate level of
platelet reactivity (7). On the basis of this preliminary
evidence, the concept of a “therapeutic window” of platelet
reactivity similar to the international normalized ratio range
used for Coumadin therapy was first hypothesized (7). The
availability of this information in the early 2000s might have
limited the speculation about the desired target for platelet
reactivity during new P2Y12 inhibitors therapy.
Since approximately 2005, an explosion of translational
research using the VerifyNow P2Y12 assay (Accumetrics,
San Diego, California), a turbidimetric-based assay that
measures the agglutination of platelets to fibrinogen-coated
beads, has occurred. This work was facilitated by the
user-friendliness of VerifyNow P2Y12 assay—a technique
that requires no pipetting, no centrifugation, and minimal
labor—allowing for enrollment of increasingly larger num-
bers of patients. However, the essential message from the
much-larger VerifyNow P2Y12 assay-based studies seems
essentially the same as the one from conventional
aggregometry-based studies (4).
A potential therapeutic window was first demonstrated
with impedance aggregometry (8). In this issue of JACC:
Cardiovascular Interventions, Mangiacapra et al. (9) further
explored the “therapeutic window” concept with VerifyNow
P2Y12 assay in 732 aspirin-treated elective PCI patients
either loaded with 600-mg clopidogrel or receiving a 75
mg/day maintenance dose for 5 days. The authors of the
current study should be acknowledged for their many
contributions to the field of personalized antiplatelet ther-
apy. Platelet function was measured before PCI—as in
other European studies where pre-treatment is common—
allowing the opportunity to study the relation of periproce-
[
l
s
s
w
c
e
t
m
T

fi
7
3
p
p
t
D
D
p
o
H
i
(
(
t
o
s
o
r
r
a
i
t
h
r
c
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 5 , N O . 3 , 2 0 1 2 Tantry et al.
MA R C H 2 0 1 2 : 2 9 0 – 2 Editorial Comment
291dural events (MI and bleeding) to on-treatment reactivity.
The 30-day net adverse event rate (occurrence of ischemic
events [death, MI defined as creatine kinase-myocardial band
3 upper limit of normal, revascularization] or bleeding
Thrombolysis In Myocardial Infarction major bleeding or
arge entry-site (10 cm) hematoma]) was 12.3% and is
imilar to the frequency reported in other studies by the
ame authors where periprocedural MIs and bleeding events
ere captured (10–12). In addition, the receiver-operating
haracteristic (ROC) curve-defined cutpoints for ischemic
vents and bleeding were very similar to the current study.
Importantly, in the current study, approximately 70% of
he ischemic events were periprocedural MIs, and approxi-
ately 80% of bleeding events were entry site hematomas.
he ROC curve-defined cutpoint for ischemic events was
239 P2Y12 reaction units (PRU) (sensitivity 63%, speci-
city 70%) and for bleeding was 178 PRU (sensitivity
8%, specificity 63%). A patient-based meta-analysis (n 
,059) of studies employing VerifyNow P2Y12 assay in PCI
atients lends further support to the clinical utility of
latelet function testing; patients with230 PRU had twice
he ischemic event rate (13). Most recently, in the ADAPT-
ES (Assessment of Dual AntiPlatelet Therapy with
rug-Eluting Stents) registry that enrolled even more
atients (n  8,575), a 230 PRU was attributable to 40%
f 30-day probable or definite ST occurrence, and when
PR was defined as PRU 208, the level of attribution
ncreased to approximately 50% (14).
On the basis of ROC curve analysis, Mangiacapra et al.
9) proposed a therapeutic window with specific thresholds
PRU 179 to 238) to define a group at lower risk for both
30-day ischemic and bleeding events. A central question is
whether ROC curve analysis is the optimal method to
determine a potential therapeutic window for personalized
antiplatelet therapy. The largest prospective randomized
personalized antiplatelet study, GRAVITAS (Gauging Re-
sponsiveness with A VerifyNow P2Y12 assay-Impact on
Thrombosis And Safety), where periprocedural events were
not captured, failed to demonstrate the clinical usefulness of
personalizing antiplatelet therapy on the basis of a 230-
PRU ischemic cutoff (15). In a subanalysis of GRAVITAS
in patients treated with standard-dose clopidogrel, a lower
ischemic cutpoint—approximately 170 PRU—was associ-
ated with optimal identification of patients destined to
experience 6-month ischemic event occurrence; patients
with a PRU 170 were ischemic event-free—in these
patients the sensitivity of the test was 100% (15).
Among ischemic events, ST is the most catastrophic.
Therefore, it could be suggested that the ischemic “cutoff”
should be based not on an ROC curve analysis but on a
cutoff with very high sensitivity to guarantee immunity or
near immunity to this event. In the current study, all 4
patients with 30-day ST had PRU 239. On the basis of
the much larger ADAPT-DES registry, the prevalence ofST was approximately 0.24% in the lowest 2 quintiles (PRU
160), compared with 0.78% in the upper 2 quintiles (PRU
217) (14). Importantly, approximately 50% of the
ADAPT-DES patients presented with acute coronary syn-
dromes, whereas the current study enrolled only stable
patients. Therefore, the optimal ischemic cutoff might be
higher in the lower-risk patient group studied by Mangia-
capra et al. (9). The cutpoint for periprocedural MI and ST
might also differ, because the underlying mechanisms are
not entirely shared.
An alteration in antiplatelet therapy intended to increase
platelet reactivity in a patient deemed “at risk” for bleeding
on the basis of ROC curve analysis might have a dire clinical
consequence: the occurrence of ST. Approximately one-half
of the ischemic events in the current study occurred in
patients with PRU below the proposed ischemic cutoff, and
approximately 25% of bleeding events occurred in patients
with a PRU above the bleeding cutoff (9). This significant
event occurrence rate within the proposed window poses a
challenge for its clinical utility.
In the current study most of the bleeding events were
vascular access site-related (9). These events might not be
“platelet-centric” in mechanism but rather influenced by
multiple factors, including arterial access, local techniques to
achieve hemostasis, vessel wall characteristics, and concom-
itant medications. Thus, the current bleeding cutoff might
have been driven upward in an ROC curve analysis by
vascular site-related bleeding events unrelated to platelet
reactivity. Large entry site hematoma frequency might be
reduced by radial access (used in only approximately 4% in
the current study). A lower PRU in the setting of radial
access might ensure greater protection against the occur-
rence of the catastrophic event, ST, but at the same time
lessen bleeding risk. Unlike the data for ST, a highly
“platelet-centric” event, the data available linking platelet
function to bleeding are much less robust. Others have
suggested a PRU bleeding threshold much lower than
Mangiacapra et al. and Campo et al. (9,16). The authors
also proposed to treat patients with HPR with more
potent P2Y12 blockers (9). However, most patients
reated with either prasugrel or ticagrelor will have
n-treatment PRU 180, thus falling outside their
uggested therapeutic window (17,18).
At this time, the evidence is strong for a link between
n-treatment platelet reactivity and ischemic event occur-
ence, particularly ST. The level of platelet reactivity where
isk increases is likely influenced by the acuity of the disease
nd might explain some of the differences in reported
schemic thresholds. However, the evidence for a bleeding
hreshold seems more tenuous and is likely related to the
eterogeneous underlying mechanism. As the authors cor-
ectly concluded, larger studies are needed to validate the
oncept of a therapeutic window for P2Y12 inhibitor therapy.Certainly, an important message of this investigation and
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292many others that preceded it is that ischemic events are not
further avoided by achieving very low levels of on-treatment
reactivity. However, very low reactivity is commonly ob-
served during therapy with new P2Y12 inhibitors, raising the
ssue of unnecessary enhancement of bleeding risk in these
atients (17,18).
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